World’s First “Augmented Reality” Contact Lens Aims to Revolutionize Much More Than Medicine

World’s First “Augmented Reality” Contact Lens Aims to Revolutionize Much More Than Medicine

On the left, a picture of the Mojo lens smart contact; and a simulated image of a woman with low vision who is wearing the contact to highlight objects in her field of vision.

(Photo Credit: Mojo Vision)

Imagine a world without screens. Instead of endlessly staring at your computer or craning your neck down to scroll through social media feeds and emails, information simply appears in front of your eyes when you need it and disappears when you don't.

Keep Reading Keep Reading
Addison Nugent
Addison Nugent is a professional freelance journalist based out of Paris, France. Like so many Americans before her, she fell in love with the French capital at a young age and never left. She graduated from the Sorbonne's Master of the Arts literary research program with honors in 2016, and has since pursued a career in journalism. She has accumulated a diverse portfolio of published work that includes investigative pieces, in-depth profiles, historical deep dives, and tech news. Her work has been featured in such publications as OZY, Vice Motherboard, Atlas Obscura, Dazed Digital and Messy Nessy Chic.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.